Gastroesophageal reflux disease treatment

Acute-phase gastroesophageal reflux disease treatment... 

DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 100 190-200. 

M. Pettit, Treatment of gastroesophageal reflux disease. Pharm World Sci. 27, 432-435 (2005). 

Nonpharmacologic Treatment of Gastroesophageal Reflux Disease with Lifestyle Modifications... 

The persistence or recurrence of symptoms within 14 days after the end of treatment suggests failure of ulcer healing or HP eradication, or an alternative diagnosis such as gastroesophageal reflux disease. 

Van Zyl, J., Van Rensburg, C., Vieweg, W., and Eischer, R. (2004) Efficacy and safety of pantoprazole vs ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. Digestion. 70, 61-69. 

Earley, A., Wruble, L. D., and Humphries, T. J. (2000) Rabeprazole vs ranitidine for the treatment of erosive gastroesophageal reflux disease a double-blind, randomized clinical trial. Raberprazole Study Group. Am. J. Gastroenterol. 95, 1894-1899. 

Richter, J. E., Campbell, D. R., Kahrilas, P. J., Huang, B., and Eludas, C. (2000) Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch. Intern. Med. 160, 1803-1809. 

Omeprazole (p. 167) can cause maximal inhibition of HCl secretion. Given orally in gastric juice-resistant capsules, it reaches parietal cells via the blood. In the acidic milieu of the mucosa, an active metabolite is formed and binds covalently to the ATP-driven proton pump (H+/K+ ATPase) that transports H+ in exchange for IC into the gastric juice. Lansoprazole and pantoprazole produce analogous effects. The proton pump inhibitors are first-line drugs for the treatment of gastroesophageal reflux disease. 

H2 antagonists are clinically used in the treatment of acid-related gastrointestinal conditions. Specifically, these indications may include peptic ulcer disease, gastroesophageal reflux disease, and dyspepsia. 

A 57-year-old man with extensive onychomycosis (fungal toenail infection) asks you for an evaluation. He requests a prescription for itraconazole for treatment of this problem after seeing a television advertisement for this drug. He has chronic heartburn attributed to gastroesophageal reflux disease and is treated with the proton pump inhibitor omeprazole. He is taking lovastatin for treatment of... 

A 52-year-old real estate salesperson has a 2-week history of watery diarrhea without blood. The patient states that 4 to 5 weeks ago she and her husband visited Aspen, Colorado, on a backpacking vacation and on occasion drank water from mountain streams. They were sure the water was potable, as the unspoiled, pristine area abounded with fish, beaver, and plant life. She states she has enjoyed perfect health except that she takes antacids for what she describes as gastroesophageal reflux disease. Her physical examination produced unremarkable findings. Examination of liquid stool revealed trophozoites and cysts of G. lamblia. Which of the following is the correct treatment for this disease ... 

Mosapride is a benzamide, structurally close to cisapride. This 5-HT4 receptor agonist, which is also a 5-HT3 and D antagonist, was launched for the treatment of gastroesophageal reflux disease (GERD) (Figure 8.71). 

Acute treatment of duodenal and gastric ulcers PO 40 mg/day at bedtime Duodenal ulcer maintenance PO 20 mg/day at bedtime Gastroesophageal reflux disease PO 20 mg twice a day Esophagitis PO 2-40 mg twice a day. 

Erosive esophagitis, poorly responsive gastroesophageal reflux disease, active duodenal ulcer, prevention and treatment of NSMD-induced ulcers PO 20 mg/day To maintain healing of erosive esophagitis PO 20 mg/day. 

Unlabeled Uses Prevention and treatment of stress-related mucosal damage, especially in acutely or critically ill patients treatment of gastric ulcer and rheumatoid arthritis relief of Gl symptoms associated with NSAlDs treatment of gastroesophageal reflux disease... 

Short-term treatment of symptomatic gastroesophageal reflux disease—15 mg once daily for up to 8 weeks Short-term treatment of erosive esophagitis—30 mg once daily for up to 8 to 16 weeks... 

IV form is indicated for short-term treatment (7 to 10 days) of gastroesophageal reflux disease (GERD), as an alternative to oral therapy in patients who are unable to continue taking the oral form. Safety and efficacy of injectable form as an initial treatment for GERD have not been demonstrated. 

Represents typical dose for treatment of gastric or duodenal ulcers. Doses for preventing ulcer recurrence or treating gastroesophageal reflux disease [heartburn] may be somewhat lower. 

Consequently, treatment of H. pylori infection may improve the prognosis of people with gastric ulcers and other forms of upper GI distress (dyspepsia, gastroesophageal reflux disease). Patients with clinical signs of ulcers who also test positive for this infection should receive a treatment regimen attempting to eradicate the infection. Successful treatment of an H. pylori infection may reduce or eliminate the need for subsequent antiulcer medications in patients with gastric ulcer disease.42... 

Many elderly persons, whether demented or cognitively intact, have medical conditions that disrupt sleep. Untreated insomnia and daytime sleepiness have been associated with nursing home placement and mortality. Medically ill older adults admitted to acute care hospitals are particularly vulnerable to sleep disruptions, which appear to be created as much by the various treatments and procedures, unfamiliar routines, and environmental conditions, as by the pain, anxiety, and discomfort associated with their underlying medical condition. Medical conditions especially likely to disrupt sleep are congestive heart failure, chronic obstructive pulmonary disease, Parkinson s disease, gastroesophageal reflux disease, arthritis, and nocturia. 

AstraZeneca (formerly Astra) has launched the proton-pump inhibitor esomeprazole (19) (as Nexium) as a treatment for peptic ulcer, gastroesophageal reflux disease, duodenal ulcer, and esophagitis. Esomeprazole is the (S)-enantiomer of omeprazole and was developed as a result of its improved pharmokinetic profile and better potency after oral dosing than (f )-form of omeprazole or the racemate. The dosage is higher than would be expected for a simple chiral switch. The stereogenic center is at sulfur. Detailed accounts of the development of the process have been published.189190... 

Gastroesophageal reflux disease, erosive or ulcerative, treatment 20 mg p.o. q.d. for 4-8 weeks... 

---